MEDLIVE(02192)

12.940-2.120-14.08%

Market data delayed 15 minutes

    • 涨停板操盘手
      ·
      2024-02-28
      Comment
      Report
      Smartkarma
      ·
      2023-09-10

      China Healthcare Weekly (Sep.8)- 9th VBP, Reliable Profit Model of Biotech, Medlive, China's Outlook

      ⬇ $Medlive Technology(02192)$ - 9th national VBP has begun. We analyzed the impact on companies. 23H1 reports make us realize even with negative policy, China Biotech can still have solid profit model. Medlive's outlook is uncertain Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-sep-8-9th-vbp-reliable-profit-model-of-biotech-medlive-china-s-outlook?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On Medlive Technology (02192):- https://www.smartkarma.com/entities/medlive-technology-co-ltd?utm_source=tiger_community
      China Healthcare Weekly (Sep.8)- 9th VBP, Reliable Profit Model of Biotech, Medlive, China's Outlook
      Comment
      Report
      thaigirl
      ·
      2022-07-28
      Comment
      Report
      thaigirl
      ·
      2022-07-17
      Comment
      Report
      thaigirl
      ·
      2022-07-16
      1
      Report
      thaigirl
      ·
      2022-07-15
      1
      Report
      thaigirl
      ·
      2022-05-12
      1
      Report
      Smartkarma
      ·
      2022-04-07

      Medlive Technology (2192.HK) - The Logic Has Shaken

      The medical knowledge solutions is the key cornerstone business but it's still weak. Together with fierce competition and healthcare “rational return”, the logic of Medlive's business model has shaken The revenue YoY growth, net profit YoY growth and net profit margin reached a new low in 2021. The performance of Medlive cannot meet the market's expectations of high growth. The medical knowledge solutions is the cornerstone business and vital to the attractiveness of platform for users. However, this business is not strong enough to make the outlook certain. In the fierce competition, more efforts are needed on how to convert physician resources into business value continuously. Due to unreliable logic, we are conservative about Medlive at current stage. By Xinyao (Criss) Wang - https://ww
      Medlive Technology (2192.HK) - The Logic Has Shaken
      TOPBaronLyly: This company should have great development potential, after all, medical knowledge solutions are getting more and more attention and will gradually be recognized by more and more people
      9
      Report
      Smartkarma
      ·
      2022-04-05

      Medlive - High Conviction Update 2022

      Medlive is currently trading at a FY2 EV/Revenue of 0.97x and we think Medlive’s shares are extremely cheap at the current valuation and offers a good entry point. Medlive’s shares are currently trading at HK$8.15 per share and lost almost 70% YTD which we think was due to the ongoing regulatory crackdown on tech platforms in China. Medlive's 2021 revenues grew 33.2% YoY to RMB284m while adjusted OP grew 19.0% YoY to RMB123m. Shares reacted negatively due to slowdown in top line growth. Medlive is currently trading at FY2 EV/Revenue of 0.97x compared to 34.3x when we last wrote. We think shares are extremely cheap and offers a good entry point. By Shifara Samsudeen, ACMA, CGMA - https://www.smartkarma.com/profiles/shifara-samsudeen-acma-cgma?utm_source=tiger_community On Medlive Technology
      Medlive - High Conviction Update 2022
      Comment
      Report
    • Company Profile

      Company Name
      MEDLIVE
      Market
      SEHK
      Establishment Date
      - -
      Employees
      - -
      Office Location
      - -
      Website
      - -
      Zip Code
      - -
      Phone
      - -
      Fax
      - -
      Introduction
      Medlive Technology Co Ltd is a China-based investment holding company mainly operates online professional physician platform. The Company mainly operates three segments. Its Precision Marketing and Corporate Solutions segment provides precision marketing solutions and corporate solutions. Its precision marketing solutions include digital detailing, digital marketing consulting and digital content creation services. Its revenue of its corporate solutions is primarily software as a service (SaaS). The Medical Knowledge Solutions segment mainly provides professional medical information and medical software services. The Intelligent Patient Management Solutions segment mainly provides online patient consultation and prescription services and patient management services. The Company mainly conducts its business within domestic market.
      • 1D
      • 5D
      • Day
      • Week
      • Month
      Loading ...
      High
      15.300
      Open
      15.280
      Volume%
      2.43
      Low
      12.880
      Close
      15.060
      T/O Rate
      1.59%
      errorbox banner

      抱歉,当前请求异常(-1)

      Company: TTMF Limited. Tech supported by Xiangshang Yixin.

      Email:uservice@ttm.financial